» Articles » PMID: 20456491

Reasons for Treating Secondary AML As De Novo AML

Overview
Journal Eur J Haematol
Specialty Hematology
Date 2010 May 12
PMID 20456491
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML. The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-related AML (t-AML) in 37 cases (24%). Median age at diagnosis of AML was 69 yr in secondary cases when compared to 66 yr in de novo cases (P = 0.006). In univariate analyses, secondary AML was associated with an inferior complete remission (CR) rate (P = 0.008) and poorer overall survival (OS, P = 0.003) whereas in complete remitters, disease-free survival (DFS) of secondary cases was equal to that of de novo cases. Interestingly, in all further analyses of CR-rates, OS and DFS, when correcting for the influence of age, cytogenetic abnormalities, performance status and leucocyte count (WBC), presence of secondary AML completely lost prognostic significance. We conclude that the presence of secondary AML does not per se convey an unfavourable prognosis and that patients with secondary AML should be offered the chance of benefiting from treatment according to current frontline AML protocols.

Citing Articles

Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.

Belhabri A, Heiblig M, Morisset S, Vila L, Santana C, Nicolas-Virelizier E Cancer Med. 2023; 12(16):16929-16944.

PMID: 37548369 PMC: 10501294. DOI: 10.1002/cam4.6322.


Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.

Martinez-Cuadron D, Megias-Vericat J, Gil C, Bernal T, Tormo M, Martinez-Sanchez P Haematologica. 2023; 109(1):115-128.

PMID: 37199127 PMC: 10772508. DOI: 10.3324/haematol.2022.282506.


Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells.

Sbirkov Y, Schenk T, Kwok C, Stengel S, Brown R, Brown G Front Cell Dev Biol. 2023; 11:1076458.

PMID: 37035245 PMC: 10076884. DOI: 10.3389/fcell.2023.1076458.


Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population-based study in France.

Atsou K, Rachet B, Cornet E, Chretien M, Rossi C, Remontet L Cancer Med. 2023; 12(7):8911-8923.

PMID: 36710405 PMC: 10134294. DOI: 10.1002/cam4.5645.


Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia.

Orvain C, Rodriguez-Arboli E, Othus M, Sandmaier B, Deeg H, Appelbaum F Cancers (Basel). 2023; 15(2).

PMID: 36672303 PMC: 9856876. DOI: 10.3390/cancers15020352.